#USA #New York #Faruqi & Faruqi #Lantheus Holdings #Pylarify

Investor Alert: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Lantheus Investors

Faruqi & Faruqi, LLP, a prominent national securities law firm, has launched an investigation into potential claims involving Lantheus Holdings, Inc. ( Lantheus or the Company). This inquiry primarily concerns investors who sustained losses exceeding $75,000 within the timeframe from February 26, 2025, to August 5, 2025. The firm is encouraging affected shareholders to make contact to discuss their options further.

The investigation was prompted by a series of disclosures that raised significant doubts about Lantheus' market position. Notably, as detailed in court documents, the company issued misleading statements regarding Pylarify, its medical imaging agent. These deceptive communications suggested such dynamics in pricing and performance that investors might have been misled to believe in an inflated valuation of Lantheus' stock.

Background of the Case

Faruqi & Faruqi has a proven track record, having helped recover hundreds of millions of dollars for investors since its establishment in 1995. The present investigation stems from several damaging disclosures from Lantheus in early August 2025, where the company reported disappointing quarterly results that significantly missed market expectations. The performance of Pylarify was notably underwhelming, raising red flags among investors and analysts alike.

On May 7, 2025, Lantheus' quarterly earnings report revealed revenues that fell short of what the market had anticipated. The analysis pointed specifically to Pylarify's performance, which was struggling to gain anticipated traction in the competitive landscape. The situation worsened on August 6, 2025, when the Company publicly revised down its growth projections and indicated that Pylarify had seen an 8.3% decline year-over-year.

Furthermore, the Company attributed its recent setbacks to intensifying competition, which negatively impacted its pricing power and growth outlook. The immediate response from market participants was severe, resulting in a drastic decline in share price. Following the negative announcements, Lantheus stock plummeted nearly 28.8% in a single day, from $72.83 a share to $51.87.

Legal Options for Investors

The law firm has advised that any investor affected by these financial setbacks may wish to pursue a role as the lead plaintiff in an ongoing federal securities class action against Lantheus. This role is usually reserved for the investor with the largest financial stake in the case, who will represent the collective interests of all class members. Participants have the option to engage legal counsel of their choice or remain passive class members while still benefiting from any potential recovery.

Faruqi & Faruqi also encourages individuals with additional information regarding Lantheus' conduct to step forward, especially if they are whistleblowers, former employees, or other stakeholders who might be able to contribute valuable insights into the circumstances surrounding the investigations.

Conclusion

For anyone who has invested in Lantheus and feels they may have been misled, it's critical to act swiftly. A deadline for potential lead plaintiff nominations in the class action litigation is imminent, with November 10, 2025, being the cut-off date. Interested parties can reach out to Faruqi & Faruqi directly at 877-247-4292 or 212-983-9330 (Ext. 1310), or visit their website for further information about the ongoing class action and their rights as shareholders. Staying informed and proactive is essential for stakeholders to navigate these challenging circumstances effectively.